Company Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors.
Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2007 |
| IPO Date | Oct 1, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 181 |
| CEO | Bahram Valamehr |
Contact Details
Address: 12278 Scripps Summit Drive San Diego, California 92131 United States | |
| Phone | 858 875 1800 |
| Website | fatetherapeutics.com |
Stock Details
| Ticker Symbol | FATE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001434316 |
| CUSIP Number | 31189P102 |
| ISIN Number | US31189P1021 |
| Employer ID | 65-1311552 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bahram Valamehr M.B.A., Ph.D. | President and Chief Executive Officer |
| Cindy R. Tahl J.D. | Chief Legal and Compliance Officer and Corporate Secretary |
| Victor Hong | Vice President of Corporate Development and Finance |
| Jessica Francis | Vice President Of Human Resources and Operations |
| Andrew Henry | Senior Vice President of Clinical Operations |
| Dr. Tunde Babalola | Senior Vice President of Technical Operations |
| Dr. Yu Cai | Head of Intellectual Property and Assistant General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | ARS | Filing |
| Apr 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 6, 2025 | 144 | Filing |
| Mar 5, 2025 | 10-K | Annual Report |
| Mar 5, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 144 | Filing |
| Jan 10, 2025 | 144 | Filing |
| Jan 10, 2025 | 144 | Filing |